Diagnosis of malignant glioma: role of neuropathology

Recommendations Level I: The diagnosis of malignant glioma should be based on the histopathologic review of tissue. Level II: Both frozen section and cytopathologic evaluation are recommended for the intra-operative diagnosis of malignant glioma. Consultation from a neuropathologist specialized in brain tumor diagnosis is recommended for problematic cases. Level III: Incorporation of clinical and radiographic information with the final pathologic diagnosis is

[1]  N. Ringertz.  Grading of gliomas. , 2009 .

[2]  Pl Lantos,et al.  Greenfield's Neuropathology , 1985 .

[3]  L. J. Rubinstein,et al.  Tumors of the central nervous system , 1972 .

[4]  Dorothy S. Russell,et al.  Pathology of Tumours of the Nervous System , 1972 .

[5]  P. Burger,et al.  Frozen section interpretation in surgical neuropathology. II. Intraspinal lesions. , 1977, The American journal of surgical pathology.

[6]  O. G. Dodge,et al.  Histological Typing of tumours of the Central Nervous System , 1981, British Journal of Cancer.

[7]  P. Burger.  Use of cytological preparations in the frozen section diagnosis of central nervous system neoplasia , 1985, The American journal of surgical pathology.

[8]  G. Eide,et al.  Oligodendroglioma. Histologic Evaluation and Prognosis , 1986, Journal of neuropathology and experimental neurology.

[9]  R. McLendon,et al.  Clinicopathologic correlations in the oligodendroglioma , 1987, Cancer.

[10]  L. Lunsford,et al.  Touch preparations in the rapid intraoperative diagnosis of central nervous system lesions. A comparison with frozen sections and paraffin-embedded sections. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  K. M. Sweeney,et al.  CT-assisted stereotactic brain biopsy: value of intraoperative frozen section diagnosis. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[12]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[13]  S. Martin,et al.  Intermediate Filament Expression in Astrocytic Neoplasms , 1989, The American journal of surgical pathology.

[14]  T. H. van der Kwast,et al.  Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas , 1990, Cancer.

[15]  M. Reyes,et al.  Imprints, smears, and frozen sections of brain tumors. , 1991, Neurosurgery.

[16]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Ben H. Choi.  Surgical Pathology of the Nervous System and Its Coverings , 1992 .

[18]  Keratin intermediate filament expression in astrocytic neoplasms: analysis by immunocytochemistry, western blot, and northern hybridization. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[19]  F. Scaravilli,et al.  Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique. , 1993, Brain : a journal of neurology.

[20]  B. Scheithauer,et al.  Histological Typing of Tumours of the Central Nervous System , 1993, World Health Organization.

[21]  B. Scheithauer,et al.  Mixed oligoastrocytomas: a survival and prognostic factor analysis. , 1994, Neurosurgery.

[22]  J. Ironside.  Update on central nervous system cytopathology. II. Brain smear technique. , 1994, Journal of clinical pathology.

[23]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[24]  Susan M. Chang,et al.  Necrosis as a prognostic factor in glioblastoma multiforme , 1996, Cancer.

[25]  E G Stopa,et al.  Observer reliability in histological grading of astrocytoma stereotactic biopsies. , 1996, Journal of neurosurgery.

[26]  D. Marion,et al.  Guidelines for the management of severe head injury. Brain Trauma Foundation. , 1996, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[27]  H. Wakimoto,et al.  Prognostic significance of Ki‐67 labeling indices obtained using MIB‐1 monoclonal antibody in patients with supratentorial astrocytomas , 1996, Cancer.

[28]  J. Moskal,et al.  Keratin expression in astrocytomas: an immunofluorescent and biochemical reassessment , 1997, Virchows Archiv.

[29]  B. Scheithauer,et al.  An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions , 1997, Cancer.

[30]  P. Burger,et al.  Stereotactic brain biopsies: specimen preparation and evaluation. , 1997, Archives of pathology & laboratory medicine.

[31]  S. Coons,et al.  The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. , 1997, Neurosurgery.

[32]  G. Barnett,et al.  Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. , 1997, Archives of pathology & laboratory medicine.

[33]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[34]  A. Markoe,et al.  Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. , 1997, International journal of radiation oncology, biology, physics.

[35]  D. Ross,et al.  A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. , 1997, Journal of neuropathology and experimental neurology.

[36]  D. Brat,et al.  Accuracy of grading gliomas on CT‐guided stereotactic biopsies: A survival analysis , 1997, Diagnostic cytopathology.

[37]  D. Louis,et al.  Use of MIB‐1 (Ki‐67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas , 1996, Journal of neuropathology and experimental neurology.

[38]  A. Chitale,et al.  Squash Preparation and Frozen Section in Intraoperative Diagnosis of Central Nervous System Tumors , 1998, Acta Cytologica.

[39]  J. Olson,et al.  Gene amplification as a prognostic factor in primary brain tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  R. McLendon,et al.  Russell and Rubinstein's pathology of tumors of the nervous system , 1998 .

[41]  H. Korf,et al.  Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases , 1998, Acta Neuropathologica.

[42]  S. Coons,et al.  Mitosis identification in diffuse gliomas , 1998, Cancer.

[43]  P. Burger,et al.  Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. , 1998, Archives of pathology & laboratory medicine.

[44]  James R.Bean.  Neurosurgery In Transition: The Socioeconomic Transformation Of Neurological Surgery , 1998 .

[45]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[46]  P. Burger,et al.  Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. , 1998, Archives of pathology & laboratory medicine.

[47]  B. Scheithauer,et al.  Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.

[48]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[49]  M. Kornfeld.  Russell and Rubinstein's pathology of tumors of the nervous system, sixth edition , 1999 .

[50]  R. Prayson,et al.  Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study. , 1999, Archives of pathology & laboratory medicine.

[51]  L. Lunsford,et al.  Use of cytological preparations for the intraoperative diagnosis of stereotactically obtained brain biopsies: a 19-year experience and survey of neuropathologists. , 1999, Journal of neurosurgery.

[52]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[53]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[54]  F. Abdul-Karim,et al.  Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading , 2000, Journal of the Neurological Sciences.

[55]  B. Kupelnick,et al.  Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. , 2001, Oncology research.

[56]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[58]  L. de Noronha,et al.  Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system , 2001, Diagnostic cytopathology.

[59]  G. Tortora,et al.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  B. Scheithauer,et al.  Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading , 2001, Journal of neuropathology and experimental neurology.

[61]  Robert B. Jenkins,et al.  Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections , 2001, Modern Pathology.

[62]  C. James,et al.  PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.

[63]  K. Aldape,et al.  Small Cell Architecture—A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme? , 2001, Journal of neuropathology and experimental neurology.

[64]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[65]  S. Raab,et al.  Interobserver variability associated with the MIB‐1 labeling index , 2001, Cancer.

[66]  K. Aldape,et al.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. , 2001, The American journal of pathology.

[67]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[68]  Andreas von Deimling,et al.  Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.

[69]  K. Roessler,et al.  High Diagnostic Accuracy of Cytologic Smears of Central Nervous System Tumors , 2002, Acta Cytologica.

[70]  R. Prayson.  Cell Proliferation and Tumors of the Central Nervous System, Part II: Radiolabeling, Cytometric, and Immunohistochemical Techniques , 2002, Journal of neuropathology and experimental neurology.

[71]  Takaaki Kirino,et al.  Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  W. K. Alfred Yung.  PATHOLOGY AND GENETICS OF TUMOURS OF THE NERVOUS SYSTEM , 2002 .

[73]  D. Brat,et al.  Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. , 2003, Frontiers in bioscience : a journal and virtual library.

[74]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[75]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[76]  D. Brat,et al.  Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression , 2003, Annals of Internal Medicine.

[77]  Erwin G. Van Meir,et al.  Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). , 2003, International journal of oncology.

[78]  Caterina Giannini,et al.  Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.

[79]  G. Barnett,et al.  Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results , 2003, Journal of Neuro-Oncology.

[80]  H. Budka,et al.  Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: Gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma , 2004, Acta Neuropathologica.

[81]  L. Nakopoulou,et al.  An immunocytochemical comparison of glial fibrillary acidic protein, S-100p and vimentin in human glial tumors , 1990, Journal of Neuro-Oncology.

[82]  G. V. van Muijen,et al.  Immunohistochemistry in melanocytic proliferative lesions , 2004, Histopathology.

[83]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  D. Brat,et al.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. , 2004, Neuro-oncology.

[85]  K. Aldape,et al.  Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma , 2004, Cancer.

[86]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[87]  W. Shapiro,et al.  Low-grade glioma: Supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults , 2004, Current neurology and neuroscience reports.

[88]  B. Scheithauer,et al.  Supratentorial gliomas: a comparative study by grade and histologic type , 1997, Journal of Neuro-Oncology.

[89]  P. Burger.  Revising the World Health Organization (WHO) Blue Book—‘Histological Typing of Tumours of the Central Nervous System’ , 2005, Journal of Neuro-Oncology.

[90]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[91]  D. Brat,et al.  Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. , 2005, American journal of clinical pathology.

[92]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[93]  Richard D Riley,et al.  Primer: an evidence-based approach to prognostic markers , 2005, Nature Clinical Practice Oncology.

[94]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[95]  Caterina Giannini,et al.  The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors , 2005, Cancer.

[96]  Daniel J. Brat,et al.  Clarifying the Diffuse Gliomas , 2005 .

[97]  R. Prayson,et al.  Role of MIB1 in Predicting Survival in Patients with Glioblastomas , 2005, Journal of Neuro-Oncology.

[98]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[99]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[100]  K. Ichimura,et al.  Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas , 2005, Journal of Molecular Medicine.

[101]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[102]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[103]  T. Zhou,et al.  O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  G. Barger,et al.  In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.

[105]  R. McLendon,et al.  Russell & Rubinstein's Pathology of Tumors of the Nervous System 7Ed , 2006 .

[106]  L. Thabane,et al.  Quality of randomized controlled trials reporting in the primary treatment of brain tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  J. Simpson,et al.  The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients , 2006, Journal of Neuro-Oncology.

[108]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Erwin G. Van Meir,et al.  Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers , 2006, Proteomics.

[110]  C. Miller,et al.  Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[112]  Erwin G. Van Meir,et al.  Attractin Is Elevated in the Cerebrospinal Fluid of Patients with Malignant Astrocytoma and Mediates Glioma Cell Migration , 2006, Clinical Cancer Research.

[113]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[114]  Richard D Riley,et al.  Prognosis research: toward evidence-based results and a Cochrane methods group. , 2007, Journal of clinical epidemiology.

[115]  Arie Perry,et al.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.

[116]  G. Reifenberger,et al.  Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.

[117]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[118]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[119]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[120]  V. Collins,et al.  Mechanisms of Disease: genetic predictors of response to treatment in brain tumors , 2007, Nature Clinical Practice Oncology.

[121]  B. Scheithauer,et al.  Tumors of the Central Nervous System , 2007 .

[122]  J. Schramm,et al.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. , 2007, The Journal of molecular diagnostics : JMD.